Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.7.0.1
Segments
3 Months Ended
Mar. 31, 2017
Segment Reporting [Abstract]  
SEGMENTS
SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisitions of BioReference and OPKO Lab and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended March 31,
(In thousands)
2017
 
2016
Revenue from services:
 
 
 
Pharmaceutical
$

 
$

Diagnostics
255,286

 
252,522

Corporate

 

 
$
255,286

 
$
252,522

Revenue from products:
 
 
 
Pharmaceutical
$
22,231

 
$
19,899

Diagnostics

 

Corporate

 

 
$
22,231

 
$
19,899

Revenue from transfer of intellectual property:
 
 
 
Pharmaceutical
$
18,579

 
$
18,616

Diagnostics

 

Corporate

 

 
$
18,579

 
$
18,616

Operating (loss) income:
 
 
 
Pharmaceutical
$
(22,637
)
 
$
(1,330
)
Diagnostics
(3,101
)
 
(2,355
)
Corporate
(15,969
)
 
(23,833
)
 
$
(41,707
)
 
$
(27,518
)
Depreciation and amortization:
 
 
 
Pharmaceutical
$
6,775

 
$
2,861

Diagnostics
18,925

 
19,320

Corporate
30

 
18

 
$
25,730

 
$
22,199

Loss from investment in investees:
 
 
 
Pharmaceutical
$
(1,814
)
 
$
(2,050
)
Diagnostics
(317
)
 
(295
)
Corporate

 

 
$
(2,131
)
 
$
(2,345
)
Revenues:
 
 
 
United States
$
255,641

 
$
252,438

Ireland
20,717

 
22,144

Chile
10,121

 
6,983

Spain
4,505

 
4,023

Israel
4,217

 
4,743

Mexico
865

 
706

Other
30

 

 
$
296,096

 
$
291,037


(In thousands)
March 31,
2017
 
December 31,
2016
Assets:
 
 
 
Pharmaceutical
$
1,286,571

 
$
1,294,916

Diagnostics
1,345,894

 
1,408,522

Corporate
127,603

 
63,181

 
$
2,760,068

 
$
2,766,619

Goodwill:

 

Pharmaceutical
$
253,204

 
$
251,817

Diagnostics
452,786

 
452,786

Corporate

 

 
$
705,990

 
$
704,603



One customer represented more than 10% of our total consolidated revenue during the three months ended March 31, 2017. As of March 31, 2017, no customer represented more than 10% of our accounts receivable balance. As of December 31, 2016, one customer represented more than 10% of our accounts receivable balance.